A novel therapy for ovarian cancer using real‑time imaging

Mareel M and Leroy A: Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 83:337–376. 2003. View Article : Google Scholar : PubMed/NCBI

Weigelt B, Peterse JL and Van't Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI

Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ and Devilee P: Genetic susceptibility for breast cancer: How many more genes to be found? Crit Rev Oncol Hematol. 63:125–149. 2007. View Article : Google Scholar : PubMed/NCBI

Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES and Georgakilas AG: Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett. 342:213–222. 2014. View Article : Google Scholar : PubMed/NCBI

Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI

Yoo HS and Park TG: Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release. 70:63–70. 2001. View Article : Google Scholar : PubMed/NCBI

Low PS and Antony AC: Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 56:1055–1058. 2004. View Article : Google Scholar : PubMed/NCBI

Lu Y, Sega E, Leamon CP and Low PS: Folate receptor-targeted immunotherapy of cancer: Mechanism and therapeutic potential. Adv Drug Deliv Rev. 56:1161–1176. 2004. View Article : Google Scholar : PubMed/NCBI

Hilgenbrink AR and Low PS: Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci. 94:2135–2146. 2005. View Article : Google Scholar : PubMed/NCBI

Santra S, Kaittanis C, Santiesteban OJ and Perez JM: Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J Am Chem Soc. 133:16680–16688. 2011. View Article : Google Scholar : PubMed/NCBI

Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003. View Article : Google Scholar : PubMed/NCBI

Heister E, Neves V, Silva SRP, Mcfadden J and Coley HM: Carbon nanotubes loaded with anticancer drugs: A platform for multimodal cancer treatmentCarbon Nanotubes for Biomedical Applications. Klingeler R and Sim RB: Springer-Verlag GmbH; Berlin: pp. 223–245. 2009

Karukstis KK, Thompson EH, Whiles JA and Rosenfeld RJ: Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem. 73:249–263. 1998. View Article : Google Scholar : PubMed/NCBI

Jakupec MA, Galanski M and Keppler BK: Tumor-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol. 146:1–54. 2003. View Article : Google Scholar : PubMed/NCBI

Hall MD, Mellor HR, Callaghan R and Hambley TW: Basis for design and development of platinum (IV) anticancer complex. J Med Chem. 50:3403–3411. 2007. View Article : Google Scholar : PubMed/NCBI

Tyagi AK, Agarwal C, Chan DC and Agarwal R: Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 11:493–499. 2014.

Chun R, Kurzman ID, Couto CG, Klausner J, Henry C and MacEwen EG: Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. J Vet Intern Med. 14:495–498. 2000. View Article : Google Scholar : PubMed/NCBI

Harrington KJ, Syrigos KN, Uster PS, Zetter A, Lewanski CR, Gullick WJ, Vile RG and Stewart JS: Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model. Br J Cancer. 91:366–373. 2004.PubMed/NCBI